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properties for only 8 have been compared in 4 different pub-
lished studies. A common comparator in all four studies has been
the Medical Outcomes Survey Short Form (SF-36). Responsive-
ness to change and patient preferences regarding the question-
naires have been compared less frequently. Overall, the Multiple
Sclerosis Impact Scale (MSIS-29) has been shown to perform
better over a range of psychometric properties compared to the
commonly used MSQOL and the Functional Assessment in MS
(FAMS). CONCLUSIONS: MSIS-29 appears to be a psychome-
trically sound measure of QOL in MS. However, owing to the
paucity of psychometric comparisons in the MS literature,
further rigorous head-to-head comparisons of newer as well as
existing questionnaires with MSIS-29 are warranted. Such results
can guide researchers in selecting an appropriate measure for use
in clinical trials as well as routine clinical practice.
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OBJECTIVES: Understanding the real-world effectiveness of
triptans in migraine, a trial was conducted using patient-reported
outcomes to evaluate the beneﬁt of triptan therapy before and
after switching to eletriptan 40mg. METHODS: Physicians
enrolled migraineurs into an open-label treatment-satisfaction
study using web-based data collection technology. Patients’
demographic information, migraine experience, utilization of
health care resources and level of satisfaction with prior migraine
therapy (both prescription and over-the-counter treatments)
were evaluated separately for headache pain relief, speed of pain
relief and ability to return to daily activities. Patients were then
switched to eletripan 40mg and their level of satisfaction across
each outcome domain was measured for three migraine attacks.
RESULTS: Of the 2778 patients enrolled (87.1% female; mean
age, 37.4 years; 83.6% employed; averaged 5.5 attacks per
month lasting a mean duration of 11 hours; 49.9% high health
care utilizers [≥1 headache-related outpatient and/or emergency
room visit per month]), 2303 (82.9%) treated at least one
migraine attack with eletriptan 40mg. Patient-reported satisfac-
tion (4 or 5 on a 5-point scale) with eletriptan 40mg was 68.8%,
57.2% and 62.8% for headache pain relief, speed of pain relief
and ability to return to daily activities, respectively, and was sig-
niﬁcantly greater when compared with satisfaction with prior
therapy (triptan and non-triptan): 29.8%, 22.1% and 21.7%,
respectively (p < 0.001). Seventy percent of high health care uti-
lizers achieved satisfactory-to-completely-satisfactory pain relief
on eletriptan 40mg. Employed patients were signiﬁcantly more
satisﬁed (64.2%) than unemployed patients (56%) with eletrip-
tan 40mg (p < 0.01). CONCLUSION: Increased level of patient
satisfaction on eletriptan when compared with prior therapy
indicates a signiﬁcant unmet need for optimized treatment of
acute migraine in this patient population. Further research is
required to determine whether increased satisfaction is associ-
ated with decreased health care utilization. Such real-world effec-
tiveness data might be useful in formulary decision making and
health care beneﬁt design.
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OBJECTIVES: Determine impact of a worksite disease manage-
ment program (DMP) on work productivity loss among employ-
ees with migraines. METHODS: A total of 712 health risk
assessment questionnaires were distributed to employees of a
medical group (64% response rate), with 180 identiﬁed as
migraineurs using IHS criteria from respondent self-report.
Migraineurs were given a DMP which included: 1) tailored
behavioral print material; 2) headache diary; 3) access to work-
site presentations (“Lunch & Learns”) by a physician on trig-
gers, diagnosis and treatment options, Q&A, and instruction on
completion of the MIDAS (Migraine Disability Assessment); 4)
headache tipsheets and suggestions for web-based resources; and
5) access to worksite physicians for same-day treatment. A
follow-up questionnaire distributed 12 months post-launch
revealed no nonresponse bias between respondents (n = 73) and
nonrespondents (n = 107). The primary dependent measure of
the evaluation was work productivity loss (WPL), which com-
bined absenteeism (full and partial days missed due to headache)
and presenteeism (days worked with headache and self-reported
productivity) during the past four weeks. RESULTS: Only 52%
of migraineurs recalled reading the provided tailored educational
print materials on managing their headaches, 28% reported
attending Lunch & Learn sessions, and 7–13% used other
program components. Mean lost productivity dropped only
slightly from baseline to follow-up (8.3 v 7.3 hours, NS).
However, subgroup analyses revealed the program was effective
in signiﬁcantly (p < 0.05) reducing WPL for employees who 1)
increased their level of conﬁdence to control their headaches
after program exposure (6.7 v. 2.3 hours), and 2) sought medical
care for headaches and used migraine prescription medications
(13.4 v. 4.1 hours). CONCLUSIONS: Overall, the DMP failed
to reduce productivity loss among employees with migraines;
however promising ﬁndings were observed for selected groups.
Future programs need to identify effective strategies to improve
self-conﬁdence in headache management and to engage more
migraineurs in seeking medication attention.
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OBJECTIVES: The objective was to determine whether there
was a signiﬁcant association between Body Mass Index scale
(underweight, normal, overweight, moderate obesity, severe
obesity, and very severe obesity) and national medical expendi-
tures (dependent variable) for persons, 18 to 65 years of age,
controlling for demographics of gender, race, marital status, and
education. METHODS: The database used was the Medical
Expenditure Panel Survey (MEPS) for the year 2002. A two-part
model was used to analyze the association between obesity and
health care expenditures. The ﬁrst part was a logistic regression
or binary model, in which expenditures were either existent or
non-existent. This model was adjusted by the demographic vari-
ables of gender, age, race, marital status, and education. The
second part modelled the relationship between expenditure and
BMI. This model was also adjusted by the study demographics.
Park’s test was performed to determine which distribution family
ﬁt the data. In order to accomplish this a General Linear Model
(GLM) framework was used. RESULTS: Approximately 64% of
the sample was overweight or obese. The rest were normal or
underweight. According to the logistic regression, Body Mass
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Index (BMI) was signiﬁcantly associated with positive expendi-
tures. Higher BMI was correlated with more positive expendi-
tures. The most appropriate framework for the GLM was the
Gamma distribution. The GLM showed that higher BMI was
associated with greater expenditures. Age, gender, and marital
status (separated and never married) were signiﬁcantly as-
sociated with health care expenditures. Degree of education
(Bachelor and Masters) was also signiﬁcantly related but 
negatively correlated. CONCLUSIONS: Health care expendi-
tures are signiﬁcantly associated with BMI using a gamma dis-
tribution, where age, gender, marital status and education are
also signiﬁcant.
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OBJECTIVES: Obesity has become an important public health
issue because of its link to high rates of avoidable and prema-
ture morbidity and mortality, especially due to its association
with severe cardiovascular diseases and cancer. The objective of
this study is to describe the mortality attributed to obesity in
Spain in 2000 and its associated costs. METHODS: Mortality
associated with obesity was obtained by combining mortality
data for the general population and the PAR (Population Attrib-
utable Risk). Loss of potential productive life years attributable
to obesity was estimated, based on activity rates of population
under 65 years old. The costs associated to premature death were
then obtained by multiplying by mean wage ﬁgures. RESULTS:
18.7% of all the deaths could be attributed to obesity. This mor-
tality was similar in males and females (10.116 vs 11.537). The
life years potentially lost attributable to obesity were 23,510, dis-
tributed as follows: 1015 for DM type 2, 422 for hypertension,
8925 for ischemic heart disease, 3854 for stroke, 61 for
osteoarthritis, 3330 for colorectal cancer, 897 for ovarian cancer,
3649 for breast cancer, 1359 for vesicle cancer. The loss of pro-
ductivity years, based on activity rates for population under 65
years was 12.309, meaning a loss of €294 million. CONCLU-
SIONS: This economic approach to premature death shows how
deep is the impact of obesity on the productivity of our country.
But obesity and its comorbidities increase with age, reaching its
highest prevalence after 65 years old, meaning that the real
impact of obesity in mortality in general is even more signiﬁcant.
Given that abdominal obesity has been proved to be a speciﬁc
risk factor for cardiovascular events, and that its prevalence 
is higher than obesity itself, this analysis could be completed 
by including this parameter, once the data are available in the
literature.
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OBJECTIVES: Rimonabant is a new agent currently seeking
approval by the FDA for the indications of smoking cessation
and treatment of obesity. This study estimates the cost–utility
ratio of rimonabant for the treatment of obesity using data from
two phase–III clinical trials. METHODS: Data from the Rimon-
abant in Obesity (RIO) Europe and RIO Lipids trials, two ran-
domized, double-blinded, placebo-controlled, parallel group,
ﬁxed-dose, multicenter studies, were used to model utilities
gained as increase in quality of life due to a temporary weight
loss during a one-year treatment with rimonabant. In this study,
two separate analyses were conducted: ﬁrst, treatment with
rimonabant 20mg/d plus dietary modiﬁcation versus placebo
plus dietary modiﬁcation and second, comparison of treatment
as above with a hypothetical no intervention group. The second
analysis assumed no reduction in BMI [kg/m2] and zero costs for
the no intervention group. The temporary weight loss for the
treatment and placebo group was calculated assuming a weight
regain to baseline within 3 years after treatment cessation. Costs
included drug acquisition costs (estimated based on costs for
comparable agents), physician ofﬁce visits and dietary counsel-
ing. Efﬁcacy estimates were discounted at 3%. RESULTS:
Reduction in BMI was 2.395 and 0.601 for treatment and
placebo, respectively. In the second analysis, comparison to no
intervention, treatment resulted in a BMI reduction of 3.133.
The incremental cost–utility ratio is $38,884 per QALY com-
paring treatment to placebo and $28,364 per QALY compared
to no intervention. Sensitivity analysis revealed that the results
are sensitive to variations in acquisition costs and sustainability
of weight loss. CONCLUSIONS: Rimonabant is able to increase
quality of life by reducing body weight. This beneﬁt is achieved
at considerable costs; however, the cost–utility ratios are well
below the currently accepted thresholds.
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OBJECTIVE: To predict effects over time on cardiometabolic
risk factors of adding rimonabant to diet and exercise in over-
weight/obese patients. Both weight-dependent and weight-
independent effects of treatment were examined in order to carry
out a Discrete Event Simulation (DES). The DES predicts the
time-dependent course of individual patients’ data according to
treatment. METHODS: Data were taken from 4 RIO trials in
over 6600 overweight/obese patients who received once-daily
rimonabant 20mg (or placebo) on top of diet and exercise. Time-
dependent functions of individual changes in weight, waist cir-
cumference, cholesterol, HDL-cholesterol, triglycerides, HbA1c,
fasting glucose, and blood pressure were required for the DES.
Change over time was analyzed in pooled trial data using a two-
step process: 1) Logistic regressions predicted whether the para-
meter would decrease, and 2) fractional polynomials predicted
change as a function of time and other factors. Random-effects
were included to account for within and between patient vari-
ance. RESULTS: One year of treatment induced cardiometabolic
improvements following a curvilinear course with steep initial
changes and subsequent stabilization after six to nine months.
To properly reﬂect these time-dependent changes, several time
parameters were required in each equation. The degree of change
over time depended on baseline levels and other patient charac-
teristics and on weight changes, but rimonabant 20mg provided
an additional, weight-independent, statistically-signiﬁcant, effect
(OR for worsening 0.36–0.88 depending on outcome consid-
ered). CONCLUSIONS: Multivariate time-dependent analytic
techniques can provide the detailed estimates required for dis-
crete event simulation. Growth curves enable estimation of the
course of each simulated individual over time by providing for
realistic modeling of risks and facilitate probabilistic sensitivity
analyses. These analyses provided a detailed, accurate reﬂection
